This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

David W. Kaufman, ScD; Donald R. Miller, MS; Lynn Rosenberg, ScD; Susan P. Helmrich, MS; Paul Stolley, MD; David Schottenfeld, MD; Samuel Shapiro, MB, FRCP(E)

JAMA. 1984;252(1):63-67.

Abstract
The relation between the risk of breast cancer and the use of noncontraceptive estrogens was investigated in a hospital-based study of 1,610 women with breast cancer and 1,606 with other conditions. The overall relative risk estimate for conjugated estrogens first taken at least 18 months before admission, compared with never-use of any noncontraceptive estrogens, was 0.9 (95% confidence interval, 0.7 to 1.1). For other estrogens first taken at least 18 months before admission, the estimate was 0.8 (0.6 to 1.1). The results were similar when known risk factors for breast cancer were taken into account. Among postmenopausal women, conjugated estrogens did not appear to increase the risk of breast cancer, even when taken for many years or in the distant past. There was no evidence of an increased risk due to conjugated estrogen use among subgroups of women defined according to various risk factors for breast cancer. The results of this study suggest that noncontraceptive estrogens do not increase the risk of breast cancer.

(JAMA 1984;252:63-67)

Author Affiliations
From the Drug Epidemiology Unit, School of Public Health, Boston University School of Medicine (Drs Kaufman, Rosenberg, and Shapiro and Mr Miller and Ms Helmrich); The Clinical Epidemiology Unit, Section of General Medicine, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia (Dr Stolley); and the Epidemiology and Preventive Medical Service, Memorial-Sloan Kettering Cancer Center, New York (Dr Schottenfeld).

Footnotes
Reprint requests to Drug Epidemiology Unit, School of Public Health, Boston University School of Medicine, 1371 Beacon St, Brookline, MA 02146 (Dr Kaufman).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Breast cancer risk with postmenopausal hormonal treatment
Collins et al.
Hum Reprod Update 2005;11:545-560.
ABSTRACT | FULL TEXT  

The Critical Role of Alcohol Consumption in Determining the Risk of Breast Cancer with Postmenopausal Estrogen Administration
Zumoff
J. Clin. Endocrinol. Metab. 1997;82:1656-1658.
FULL TEXT  

Hormone Replacement Therapy and Breast Cancer Risk
Gambrell
Arch Fam Med 1996;5:341-348.
ABSTRACT  

Breast Cancer and Estrogen Therapy
Blair
JAMA 1994;272:1004-1004.
ABSTRACT  

Estrogen Replacement Therapy in Breast Cancer Survivors: A Time for Change
Cobleigh et al.
JAMA 1994;272:540-545.
ABSTRACT  

Hormonal Treatment of Postmenopausal Women
Belchetz
NEJM 1994;330:1062-1071.
FULL TEXT  

Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women
Grady et al.
ANN INTERN MED 1992;117:1016-1037.
ABSTRACT  

The Postmenopausal Estrogen/Breast Cancer Controversy
Henrich
JAMA 1992;268:1900-1902.
ABSTRACT  

A Meta-analysis of the Effect of Estrogen Replacement Therapy on the Risk of Breast Cancer
Steinberg et al.
JAMA 1991;265:1985-1990.
ABSTRACT  

Menopausal Estrogen Replacement Therapy and Breast Cancer
Dupont and Page
Arch Intern Med 1991;151:67-72.
ABSTRACT  

The Risk of Breast Cancer in Postmenopausal Women Who Have Used Estrogen Replacement Therapy
Wingo et al.
JAMA 1987;257:209-215.
ABSTRACT  

Adverse Effects of Drugs -- Their Causes and Prevention
Parke
The Journal of the Royal Society for the Promotion of Health 1985;105:39-46.
 

When Is the Evidence for 'No Association' Sufficient?
Hulka
JAMA 1984;252:81-82.
ABSTRACT